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Introduction: Mortality and disability following ischemic stroke (IS) remains unacceptably high with respect to the
conventional therapies. This study tested the effect of erythropoietin (EPO) on long-term neurological outcome in
patients after acute IS. This study aimed to evaluate the safety and efficacy of two consecutive doses of EPO
(5,000 IU/dose, subcutaneously administered at 48 hours and 72 hours after acute IS) on improving the 90-day
combined endpoint of recurrent stroke or death that has been previously reported. A secondary objective was to
evaluate the long-term (that is, five years) outcome of patients who received EPO.
Methods: This was a prospective, randomized, placebo-controlled trial that was conducted between October
2008 and March 2010 in a tertiary referral center. IS stroke patients who were eligible for EPO therapy were
enrolled into the study.
Results: The results showed that long-term recurrent stroke and mortality did not differ between group 1
(placebo-control; n = 71) and group 2 (EPO-treated; n = 71).
Long-term Barthel index of <35 (defining a severe neurological deficit) was lower in group 2 than group 1
(P = 0.007). Multiple-stepwise logistic-regression analysis showed that EPO therapy was significantly and independently
predictive of freedom from a Barthel index of <35 (P = 0.029). Long-term major adverse neurological event
(MANE; defined as: death, recurrent stroke, or long-term Barthel index < 35) was lower in group 2 than group 1
(P = 0.04). Log-Rank test showed that MANE-free rate was higher in group 2 than group 1 (P = 0.031). Multiple-stepwise
Cox-regression analysis showed that EPO therapy and higher Barthel Index at day 90 were independently predictive of
freedom from long-term MANE (all P <0.04).
Conclusion: EPO therapy significantly improved long-term neurological outcomes in patients after IS.
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Acute ischemic stroke (IS) accounts for greater than
70% of all types of acute stroke and is a leading cause of
death, disability, and dependence worldwide. Despite
new diagnostic tools [1,2] and the refinements of new
anti-platelet agents [3,4], the morbidity, mortality, and
residual severe disability following IS have remained un-
acceptably high over decades with respect to those of
conventional therapies [5,6]. Most patients with disabil-
ities from IS remain dependent on others and usually
have unfavorable long-term outcomes [7,8]. Evidence is
growing that thrombolytic therapy with tissue plasmino-
gen activator (tPA) may significantly improve patients’
clinical outcome after acute IS; however, not all acute IS
patients fit the criteria for tPA therapy [9-11]. A new,
safe, and efficacious treatment option needs to be devel-
oped for those patients with acute IS who are not candi-
dates for tPA therapy.
Erythropoietin (EPO) was first utilized for treating
anemic patients of various etiologies, such as patients
with end-stage renal disease on regular hemodialysis
[12,13]. Intriguingly, EPO also appears to have pleio-
tropic effects, such as anti-ischemic and anti-apoptotic
properties [14-16], promotion of neovascularization,
mobilization of endothelial progenitor cells (EPCs), and
enhancement of angiogenesis [17-19]. EPO has previ-
ously been prescribed to acute IS patients in some clin-
ical studies, but the neuroprotective effect of EPO is
poorly documented and results have been inconsistent
[20-22]. Given the pleiotropic effects of EPO therapy,
the inconsistent clinical outcomes of EPO therapy after
acute IS in clinical reports and our previous finding that
an increase in circulating levels of EPCs in patients after
acute IS was significantly associated with favorable clin-
ical outcomes [23], we performed a prospective, ran-
domized, and placebo-controlled trial [24]. The primary
objective of this clinical trial was to evaluate the safety
and efficacy of two consecutive doses of EPO (5,000 IU
per dose, subcutaneously administered at 48 hours and
72 hours after acute IS, Epoetin beta; Roche) on improv-
ing the 90-day combined endpoint of recurrent stroke or
death [24]. The secondary objectives of this study were:
to establish the time course of circulating levels of EPCs
in patients after acute IS; to investigate the ability of two
doses of EPO to enhance circulating EPC levels; and to
assess 5-year outcomes of patients who received EPO
therapy after acute IS. We report, herein, the findings of
the 5-year outcomes of this clinical trial.
The two doses of EPO administration to the acute IS
patients were basic in consideration of safety and the
clinical practice of EPO use for hemodialysis patients
each week. Additionally, the chosen time point of EPO
treatment at 48 hours and 72 hours after acute IS was
owing to the fact that time was required for magneticresonance imaging (MRI) study and enrollment as well
as the delay in presentation to hospital for most acute IS
patients.
Materials and methods
Study protocol and calculation of sample size for the
specific objective
This clinical trial was approved by the Institutional
Review Committee on Human Research in Chang Gung
Memorial Hospital (No 96-1381A) in 2007 and was con-
ducted at Kaohsiung Chang Gung Memorial Hospital.
Informed consent was obtained from all participating
patients or their legal representatives. Funding for this
study was delivered by a program grant from the
National Science Council, Taiwan, Republic of China
(NSC-97-2314-B-182A-090-MY2).
This was a prospective, randomized, placebo-controlled
trial. The study included consecutively admitted acute
IS patients who were not candidates for tPA therapy at
a single facility between October 2008 and March 2010.
The study design protocol, definitions and exclusion
criteria, calculation of sample size for specific objec-
tives, neurological assessment methods, blood sampling
and assessment of circulating EPC levels, and medica-
tions have been extensively detailed in our previous
report [24], and were described because the study in-
cluded consecutively admitted acute IS patients at a
single facility between October 2008 and March 2010.
For the primary objective of the study, an estimated
sample size of 106 study patients in each group was
based on the effective size with α = 0.05, a power of
80%, and anticipation of a combined end point of
14.0% in placebo control versus 4.0% with EPO therapy.
For the secondary objective of this study, an estimate
sample size of 93 study patients in each group was
based on the effective size with α = 0.05, a power of
80%, an average difference in the circulating level of
EPCs between the EPO therapy and placebo-control
groups of 0.32%, and a standard deviation of circulating
level of EPCs in EPO therapy of 0.7%. A 20% rate of
protocol violations and incomplete follow-up were as-
sumed. Calculation of the sample size for the specific
objective was based on our recent report [23].
Definition of ischemic stroke, and inclusion and
exclusion criteria
The definition of acute IS and the exclusion criteria have
been described in our previous report [24]. In detail,
stroke was defined as sudden onset of loss of global or
focal cerebral function persisting for more than 24 hours.
Patients of any age with acute IS were eligible. Inclusion
criteria included a score >2 on the National Institutes of
Health Stroke Scale (NIHSS; scores up to 8 indicate
moderate neurological status disability) and a time
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sampling (at 48 hours after IS) and study drug adminis-
tration (time to treatment just after blood sampling). Pa-
tients with history of the following were excluded from
the study: intracranial hemorrhage, surgery or trauma
within the preceding 3 months, abnormal liver function,
hematology disorders, renal insufficiency (serum creatin-
ine >1.5 mg/dl), malignancy, febrile disorders, acute or
chronic inflammatory disease at study entry, liver cirrho-
sis, atrial fibrillation, congestive heart failure, contraindi-
cations for MRI examination, no evidence of acute IS by
MRI study, myeloproliferative disorder, antibodies or be-
ing allergic to EPO, pregnancy, tPA therapy for acute IS,
or a hemoglobin level >15.0 gm/dl.
Neurological assessment
Evaluation of the physical function and degree of neuro-
logical impairment in the stroke patients was based on
the NIHSS [25] during the acute (48 hours), convales-
cent (day 21), and chronic (day 90) phases of stroke by
neurologists blinded to the treatment allocation (double-
blind study). Moderate neurological impairment (that is,
neurological sequelae that require partial support in
daily activities) was defined as a score ≥8 on the NIHSS,
a modified criterion reported previously [26]. In addition
to the NIHSS, assessments only during admission in-
cluded functional measures.
The Barthel Index [27], which ranges from 100 (no
deficit) to 0 (complete dependence or death), was uti-
lized for long-term functional assessment as evaluated
by neurologists blinded to the treatment allocation
(double-blind study). Barthel Index <35 was defined as a
severe disability (life dependence) [28-31]. A long-term
major adverse neurological event (MANE) was defined
as recurrent stroke, Barthel Index <35, or long-term
mortality (defined as death observed >90 days after
acute IS). All of these variables were meticulously
documented prospectively.
Brain computerized tomography and MRI definition of
acute ischemic stroke
The radiological diagnosis of acute IS included brain
computed tomography; that is, a new finding of low
attenuation density in the focal or diffuse brain area.
Additionally, the MRI findings of acute IS were defined
as follows: a typical acute IS (24 hours to 1 week) ap-
pears hyperintense on T2-weighted, diffusion-weighted,
and fluid-attenuated inversion recovery images; and ap-
pears hypointense on T1-weighted image and apparent
diffusion coefficient mapping.
Protocol for 5-year follow-up
All patients who survived acute IS were discharged from
hospital. Self-caring patients returned home. Dependentpatients with severe disability were transferred to nurs-
ing and rehabilitation centers for special care, and were
regularly followed-up in outpatients and/or by telephone.
Number of patients eligible for long-term follow-up
In this clinical trial, 84 patients received placebo therapy.
One patient died during hospitalization, leaving 83 pa-
tients who were followed-up in the outpatient depart-
ment for 90 days. Of these, six patients declined
involvement in the long-term follow-up study and were
therefore withdrawn from the study after day-90 IS.
An additional six patients were lost to follow up after
day-90 IS. The remaining 71 patients served as group 1
(placebo control) of this long-term follow-up study.
Another 83 patients received EPO therapy. Two pa-
tients died during hospitalization, leaving 81 patients
who were followed-up in the outpatient department for
90 days. Of these, five patients declined involvement in
the long-term follow-up study and were therefore with-
drawn from the study after day-90 IS. An additional five
patients were lost to follow up after day-90 IS. The
remaining 71 patients served as group 2 (EPO therapy)
of this long-term follow-up study.
Definitions
Barthel Index <35 was defined as a severe neurological
deficit; this definition was modified from previous re-
ports [28,31]. Major adverse cardiac event was defined
as myocardial infarction or cardiovascular-related death.
MANE was defined as recurrent stroke after day-90 IS, a
long-term Barthel Index <35, or any cause of long-term
death (that is, death after day-90 IS).
Medications for outpatients
Aspirin was the first-choice medication for all IS patients
unless they were allergic or intolerant to it, including a
history of peptic ulcer or upper gastrointestinal tract
bleeding during aspirin therapy. Clopidogrel was used in
patients intolerant to aspirin. Other commonly used
drugs included statins, oral hypoglycemics, angiotensin-
converting enzyme inhibitors/angiotensin II type I re-
ceptor blockers, diuretics, calcium channel blocking
agents, and beta-blockers.
Statistical analyses
Data were expressed as means ± standard deviation or
percentage of patients where appropriate. For the clinical
and laboratory variables, comparisons were carried out
using an independent t test for continuous variables and
Fisher’s exact test or a chi-square test for categorical var-
iables. A log-rank test was used to determine the MANE
free rate and multiple stepwise Cox regression analysis
was used to predict freedom from long-term MANE. All
analyses were conducted using SAS statistical software
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P <0.05 was considered statistically significant.
Results
Comparison of baseline characteristics of patients with
and without erythropoietin treatment
Table 1 presents the baseline variables of acute IS pa-
tients in both groups. There were no significant differ-
ences in terms of age, gender and incidence of coronary
artery disease risk factors. Additionally, the incidences of
previous stroke by history or brain MRI, previous myo-
cardial infarction, or significant coronary artery disease
did not differ between groups 1 and 2.Table 1 Comparison of baseline characteristics between
patients treated with and without erythropoietin
at admission
Variable Group 1
(n = 71)
Group 2
(n = 71)
P valuea
Age (years) 65.6 ± 11.3 64.1 ± 11.4 0.481
Male 64.8% (46) 69.0% (49) 0.593
Hypertension 71.8% (51) 63.4% (45) 0.282
Diabetes mellitus 31% (22) 36.6% (26) 0.478
Current smoking 25.4% (18) 33.8% (24) 0.270
Previous stroke by history 19.7% (14) 23.9% (17) 0.542
Previous stroke by brain MRI 56.3% (40) 63.4% (45) 0.392
Obstructive CADb 12.7% (9) 19.7% (14) 0.255
Old myocardial infarction 7.0% (5) 9.9% (7) 0.546
RBC count (× 106/ml) 4.68 ± 0.69 4.72 ± 0.69 0.743
Hemoglobin (g/dl) 14.0 ± 1.9 14.1 ± 1.8 0.876
WBC count (× 103/ml) 7.72 ± 2.35 7.81 ± 2.48 0.821
Total cholesterol level 189.1 ± 40.1 190.2 ± 36.4 0.864
HDL (mg/dl) 50.3 ± 18.1 45.6 ± 10.9 0.062
LDL (mg/dl) 114.0 ± 35.4 118.8 ± 31.9 0.415
Creatinine (mg/dl) 1.02 ± 0.41 1.01 ± 0.38 0.916
BMI (kg/m2) 23.9 ± 3.8 24.9 ± 3.3 0.086
HbA1C 6.88 ± 1.83 6.75 ± 1.92 0.699
SBP (mmHg) 143 ± 21 145 ± 23 0.669
DBP (mmHg) 80 ± 29 83 ± 12 0.098
Carotid artery stenosisc 15.3% (11) 23.9% (17) 0.192
Statin therapy 45.8% (33) 43.7% (31) 0.794
ACEI/ARB therapy 34.7% (25) 38% (27) 0.681
Data are expressed as mean ± standard deviation or percentage (number) of
patients. Group 1, without erythropoietin treatment; Group 2, with erythropoietin
treatment. ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II type I
receptor blocker; BMI, body mass index; CAD, coronary artery disease (defined
as >50% stenosis of epicardial vessel by angiographic finding); DBP, diastolic blood
pressure; HbA1C, hemoglobin A1C; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; MRI, magnetic resonance imaging; RBC, red blood cell; SBP, systolic
blood pressure; WBC, white blood cell. aBy t test or chi-square test. bDefined as the
coronary obstruction >50% at least one epicardial vessel. cDefined as common
carotid artery or internal carotid artery stenosis >50%.The laboratory findings showed that the red blood cell
count, the white blood cell count, and the levels of
hemoglobin, total cholesterol, high-density lipoprotein,
low-density lipoprotein and creatinine were similar be-
tween groups 1 and 2. Systolic and diastolic blood pres-
sures, body mass index and the incidences of significant
carotid artery stenosis, and use of statins or angiotensin
converting enzyme inhibitor/angiotensin II type I recep-
tor blockers did not differ significantly between groups 1
and 2.
Time courses of circulating levels of EPCs and hematological
findings between groups 1 and 2
In this clinical trial, blood samples were obtained at
48 hours (acute phase) and on day 7 (recovery phase)
and day 21 (convalescent phase) after acute IS to deter-
mine the time courses of circulating levels of EPCs
(CD31/CD34+ cells and KDR/CD34+ cells) in IS patients
(see Table 2). The hematological components of patients
at day 21 were also assessed to determine any possible
impact of EPO therapy on them. The results showed
that the circulating levels of EPCs at 48 hours and on
day 7 after acute IS did not differ between these two
groups. However, by day 21 after IS, the circulating
levels of EPCs were significantly higher in group 2 than
in group 1. Conversely, the red blood cell and white
blood cell counts and the levels of hematocrit and
hemoglobin did not differ between groups 1 and 2.
These findings implicate that this regimen of EPO therapy
slowly enhanced the circulating levels of EPCs but did not
significantly affect the hematological components.Table 2 Time courses of circulating level of EPCs and
hematological findings between the two groups of patients
Variable Group 1
(n = 71)
Group 2
(n = 71)
P value
Circulating level of EPCs at 48 hours
CD31/CD34 (%) 1.69 ± 1.01 1.59 ± 0.91 0.514
KDR/CD34 (%) 1.34 ± 0.92 1.31 ± 0.76 0.823
Circulating level of EPCs at day 7
CD31/CD34 (%) 1.35 ± 0.76 1.51 ± 1.12 0.343
KDR/CD34 (%) 1.26 ± 0.82 1.20 ± 0.73 0.623
Circulating level of EPCs at day 21
CD31/CD34 (%) 1.64 ± 0.80 2.30 ± 1.53 0.04
KDR/CD34 (%) 1.23 ± 0.73 1.78 ± 1.26 0.004
RBC count (× 106/ml) on day 21 4.49 ± 0.72 4.47 ± 0.70 0.839
Hemoglobin (g/dl) on day 21 13.39 ± 1.73 13.52 ± 1.85 0.693
Hematocrit (%) on day 21 40.12 ± 4.88 40.54 ± 5.22 0.661
WBC count (× 103/ml) on day 21 7.36 ± 2.41 7.09 ± 3.14 0.272
Data are expressed as mean ± standard deviation of patients. Group 1, without
erythropoietin treatment; Group 2, with erythropoietin treatment. EPC,
endothelial progenitor cell; RBC, red blood cell; WBC, white blood cell.
Table 4 Univariate logistic regression analysis of predictors
for long-term Barthel Index <35 after ischemic strokea
Variables Odds ratio 95% confidence
interval
P value
ACEI/ARB 0.26 0.001 to 0.573 0.021
Old stroke history 15.066 1.180 to 192.33 0.037
CD31/CD34 level at day 21 0.372 0.144 to 0.957 0.04
Erythropoietin 0.216 0.052 to 0.879 0.035
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II type I receptor
blocker. aLong-term Barthel Index defined as the measurement that represented
the final neurological status estimated at the end of the study period.
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and long-term clinical outcome between groups 1 and 2
The scores from the NIHSS and the Barthel Index upon
presentation (at 48 hours after acute IS) were similar be-
tween groups 1 and 2 (see Table 3). Additionally, the
short-term (≤90-day) mortality and the Barthel Index on
day 90 did not differ between groups 1 and 2. Further-
more, the mean long-term Barthel Index also did not
differ between groups 1 and 2. Subgroup analysis, how-
ever, revealed that the occurrence of a long-term Barthel
Index <35 or <40 and short-term (≤90-day) recurrent
stroke were significantly lower in group 2 than in group 1.
The incidences of recurrent stroke, major cardiac events,
long-term recurrent stroke, and cumulative long-term
mortality showed no differences between groups 1 and 2.
The incidence of long-term MANE was significantly lower
in group 2 than in group 1.
Univariate and multivariate logistic regression analysis of
predictors for long-term Barthel Index <35
Univariate analysis (Table 4) of baseline variables in
Tables 1, 2 and 3 showed that a history of previous
stroke was significantly predictive of a long-term severe
neurological deficit (that is, Barthel Index <35). Con-
versely, EPO therapy, an increased 21-day circulating
EPC level (CD31CD34+), and angiotensin-converting en-
zyme inhibitor/angiotensin II type I receptor blocker
therapy were significantly and strongly associated with
freedom from long-term severe neurological deficit.Table 3 Comparison of short-term and long-term
neurological status and long-term clinical outcome
between the two groups of patients
Variable Group 1
(n = 71)
Group 2
(n = 71)
P value
NIHSS at 48 hours 7.8 ± 4.5 7.2 ± 4.6 0.606
Barthel Index at 48 hours 55.4 ± 35.2 52.9 ± 29.4 0.631
Short-term (≤90-day) mortality 2.8% (2) 1.4% (1) 0.560
Short-term (≤90-day) recurrent
stroke
9.9% (7) 0% (0) 0.007
Barthel Index on day 90 67.1 ± 34.5 70.5 ± 36.2 0.631
Long-term Barthel Index 72.1 ± 40.9 79.2 ± 33.3 0.332
Long-term Barthel Index <40 25.8% (15/58) 8.2% (5/61) 0.021
Long-term Barthel Index <35 29.3% (17/58) 10.3% (6/61) 0.007
Long-term recurrent stroke 23.9% (17) 15.5% (13) 0.206
Major adverse cardiac eventsa 9.9% (7) 5.6% (4) 0.346
Accumulative long-term mortality 18.3% (13) 14.1% (10) 0.494
Long-term MANE 49.3% (35) 32.4% (23) 0.04
Data are expressed as mean ± standard deviation or percentage (number) of
patients. Group 1, without erythropoietin treatment; Group 2, with erythropoietin
treatment. MANE, major adverse neurological event (defined as, long-term Barthel
Index <35, recurrent stroke, or death after day-90 ischemic stroke); NIHSS, National
Institutes of Health Stroke Scale. aDefined as myocardial infarction or death.Multivariate analysis (Table 5) showed that a history of
previous stroke was a significant independent predictor
of long-term severe neurological deficit, whereas EPO
therapy was significantly and independently predictive of
freedom from severe neurological deficit.
Univariate and multiple stepwise Cox regression analysis
of predictors for long-term MANE after ischemic stroke
Univariate Cox regression analysis (Table 6) showed that
increased age, previous stroke, and increased creatinine
level were significantly predictive of long-term MANE.
In contrast, circuiting levels of EPCs, EPO, and Barthel
Index on day 90 therapy were three significant predic-
tors of freedom from long-term MANE. Multivariate
Cox regression analysis (Table 7) showed that increased
age and creatinine level were significantly and independ-
ently predictive of long-term MANE, whereas EPO ther-
apy and higher Barthel Index on day 90 were the only
significant independent predictors of freedom from
MANE.
Correlation between long-term Barthel Index <35 and
clinical outcome
Although the tabulated data (Tables 2 and 3) and the re-
ceiver operating characteristics curve analysis (Figure 1)
each demonstrated a significant difference between the
control and the EPO-treated cohorts using a Barthel
Index cutoff point for severe outcome of either <40
or <35, the cutoff value of <35 proved to be the most
powerful predictor of long-term MANE with a sensitiv-
ity of 93.8% and a specificity of 72.7% (that is, P <0.0001,
area under the curve = 0.862).Table 5 Multiple stepwise logistic regression analysis of
predictors for long-term Barthel Index <35 after ischemic
stroke
Variable Odds ratio 95% confidence interval P value
Old stroke history 4.600 1.266 to 16.715 0.020
Erythropoietin 0.235 0.064 to 0.863 0.029
Table 6 Univariate Cox regression analysis of predictors
for MANE after ischemia stroke
Variable Hazards ratio 95% confidence
interval
P value
Age (years) 1.032 1.007 to 1.057 0.012
Old stroke by history 1.890 1.091 to 3.274 0.023
Creatinine level (mg/dl) 1.834 1.12 to 3.026 0.016
CD31/CD34 (%) 0.740 0.585 to 0.981 0.036
Erythropoietin 0.568 0.335 to 0.961 0.024
Barthel Index on day 90 0.988 0.980 to 0.996 0.004
MANE, major adverse neurological event.
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The log-rank test demonstrated that long-term freedom
from MANE was significantly higher in group 2 than in
group 1 (Figure 2) (P = 0.031).
Discussion
This study, which investigated the impact of EPO ther-
apy on long-term clinical outcome for IS patients,
yielded several striking findings. First, long-term severe
neurological deficit (that is, Barthel Index <35) and
long-term MANE were remarkably lower in patients
with EPO therapy than those with placebo. Second, EPO
therapy and higher Barthel Index on day 90 were
strongly and independently predictive of freedom from
long-term severe neurological deficit and long-term
MANE. Our findings therefore highlight that EPO could
be considered as an alternative therapeutic option for
acute IS patients who are not candidates for tPA.
Numerous clinical trials have previously extensively
investigated the clinical outcomes in patients after acute
IS [3,4,6,26,32-34]. Those IS patients who had higher
NIHSS usually had poor prognostic outcomes after acute
IS [23,26,33]. Thus, many investigators tried to find new
modalities other than the traditional therapy for IS pa-
tients. Of these new modalities, thrombolysis with tPA is
the most effective therapy for improving the prognostic
outcome [9-11]. However, relatively higher intracranial
bleeding that would cause high in-hospital mortality wasTable 7 Multiple stepwise Cox regression analysis of
predictors for MANE after ischemia stroke
Variable Hazards ratio 95% confidence
interval
P value
Age (years) 1.020 1.009 to 1.031 0.037
Creatinine 2.125 1.214 to 3.717 0.008
Erythropoietin 0.564 0.330 to 0.965 0.037
Barthel Index on day 90 0.990 0.981 to 0.999 0.024
MANE, major adverse neurological event.a concern. Of importance was the fact that not all acute
IS patients fit the criteria for tPA therapy [9-11]. EPO
therapy has therefore been extensively investigated as it
could be an alternative option for those patients not
suitable for thrombolytic therapy [6,24,35-37]. Although
not all of the clinical trial results of EPO therapy are
consistent, the results of our study [24] and previous
studies [16,38] have revealed that EPO therapy signifi-
cantly improved clinical outcomes in patients after acute
IS. Surprisingly, no long-term data have been reported
by those previous clinical trials. Importantly, this is the
first report of long-term follow-up (that is, up to 5 years)
in a prospective, randomized, and placebo-controlled
trial of EPO therapy for patients who were not suitable
for tPA therapy.
One negative but important finding was that the inci-
dence of recurrent stroke during long-term follow-up
and long-term mortality did not differ between the two
groups. Additionally, the mean long-term Barthel Index
was similar between the two groups. Subgroup analysis,
however, showed that severe long-term neurological def-
icit (that is, long-term Barthel Index <35) was substan-
tially lower in patients who had received EPO therapy
than in the placebo-control group. Furthermore, the in-
cidence of long-term MANE was significantly lower in
the EPO-treated group than in the placebo-control
group. Of particular importance, EPO therapy and
higher Barthel Index at day 90 were significantly and in-
dependently predictive of freedom from long-term se-
vere neurological deficit and long-term MANE. It is well
known that a severe neurological deficit after acute IS
increases the social burden, detrimentally affects the pa-
tient’s quality of life and social reintegration [39-41], and
is strongly associated with unfavorable long-term clinical
outcomes. Reflecting upon these factors [7,8,23,24,39-41],
our findings highlight that EPO should be considered an
alternative therapeutic modality for patients who were not
suitable for tPA therapy.
The underlying mechanisms of EPO therapy for redu-
cing long-term severe neurological deficit and MANE
remain uncertain. Interestingly, our previous study [24]
showed that EPO therapy enhanced circulating numbers
of EPCs [24], which, in turn, participated in the repair of
cerebral vasculature. Additionally, circulating EPCs con-
tributed to the maintenance and repair of cerebral vas-
culature in ischemia-related cerebrovascular dysfunction
[42]. In the present study, we found that the level of cir-
culating EPCs (Tables 4 and 5) by day 21 after IS was
significantly increased in patients with EPO treatment
compared with placebo-control patients. Accordingly,
we suggest that the increased numbers of circulating
EPCs might be recruited into the ischemic region to
augment local angiogenesis and vasculogenesis, with re-
sultant increased cerebral blood flow and improved
Figure 1 Correlation between long-term Barthel Index <35 and clinical outcome. Receiver operating characteristics (ROC) curve analysis
revealed long-term Barthel Index <35 was the most powerful predictor of long-term major adverse neurological event with a sensitivity of 93.8%
and a specificity of 72.7%, P <0.001. AUC, area under the curve.
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therapy improving neurological dysfunction may occur
through peripheral (that is, increased circulating EPC
level and then mobilization to the brain ischemic zone
for angiogenesis) rather than central (directly protected
neurons from apoptosis/death) effects. Additionally, im-
provement of anemia may be another possible effect on
improving stroke outcome because most patients have a
drop in hematocrit/red blood cells count after acute IS.
Increased age [43], previous stroke [23,24], and in-
creased creatinine [43] are well recognized as important
predictors of unfavorable clinical outcomes in the settingFigure 2 Determining the long-term major adverse neurological
event-free rate. Kaplan–Meier survival plot. Five-year cumulative
(log-rank test) freedom from major adverse neurological event (MANE)
was significantly higher in group 2 than in group 1 patients, P = 0.031.of cardiovascular and cerebrovascular diseases. In the
present study, we found that a history of previous stroke
was an independent predictor of long-term severe
neurological dysfunction. Additionally, increased age and
increased creatinine level were found to be independ-
ently predictive of long-term MANE. In this way, our
findings were consistent with the findings of previous
studies [23,24,43].
Conclusion
Patients who received EPO therapy had significantly less
long-term severe neurological deficit and significantly
less long-term MANE compared with placebo-control
patients. The results of our study encourage the use of
EPO for patients with acute IS who are not candidates
for tPA thrombolysis.
Study limitations
This study has limitations. First, the sample size of this
clinical trial was relatively small. Additionally, because of
restrictive inclusion criteria, some critically ill patients
were excluded during the initial enrollment period. The
long-term mortality rate was thus relatively low in the
current study. Accordingly, we cannot completely rule
out a statistical distortion of significant differences of
long-term mortality and recurrent stroke between these
two groups of patients. Second, the incompleteness of
follow-up data (due to patients withdrawn from the
study or lost to follow-up) introduces uncertainty re-
garding interpretation of the differences in clinical
Tsai et al. Critical Care  (2015) 19:49 Page 8 of 9outcome between these two groups of patients. Without
measuring cerebrospinal fluid concentration of EPO, we
did not know whether the improvement of neurological
function was due to central or peripheral effect or due
to both of them.
Key messages
 EPO treatment significantly ameliorates long-term
clinical outcomes in patients after acute IS.
 The results of the present study encourage the use
of EPO for patients with acute IS who are not
candidates for thrombolytic therapy.
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